Omaha, NE Streck, Inc. and Sysmex Inostics, a subsidiary of Sysmex Corporation, have announced that Sysmex Corporation has signed a worldwide supply and distribution agreement with Streck. The agreement allows Sysmex to supply Streck Cell-Free DNA BCT® and Streck Cell-Free DNA BCT® CE blood collection tubes as part of Sysmexs medical diagnostic products and services.
Streck is recognized worldwide for its innovative direct-draw blood collection tubes. Our internal studies have shown that Streck Cell-Free DNA BCT® blood collection tubes are ideal for stabilizing cell-free DNA to allow for efficient and effective collection and transport of specimens at ambient temperatures. As a result, we are including the Streck blood collection tubes with our products and services associated with our OncoBEAM assays, said Vishal Sikri, Vice President of Commercial Operations at Sysmex Inostics.
Strecks partnership with Sysmex spans more than three decades, said Connie Ryan, President and CEO at Streck. Our new agreement with Sysmex supports the collaboration of that long-term partnership and the expansion of our product portfolio.
Sysmex Inostics highly sensitive molecular diagnostic testing solutions allow for molecular genetic analysis of cell-free tumor DNA from blood or plasma, delivering an individualized approach to complement treatment decision-making in oncology. Their minimal-invasive nature reveals new possibilities for cancer management, while minimizing costs and risks inherent with tissue biopsies.
About Sysmex Inostics
Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company whose core competency is mutation detection utilizing highly sensitive technologies such as BEAMing and Plasma Sequencing. Sysmex Inostics is a trusted partner to leading pharmaceutical companies, advancing their efforts to bring the most effective personalized cancer therapies to global markets. With BEAMing being one of the most sensitive technologies available today for the detection of tumor specific somatic mutations in blood samples, Sysmex Inostics OncoBEAM services are readily available to support clinical trials and research in oncology. For more information on OncoBEAM blood testing and the BEAMing technology, refer to www.sysmex-inostics.com or email [email protected]sysmex-inostics.com
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 40 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 7,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange. For more information about Sysmex Corporation and its affiliate companies, please visit http://www.sysmex.co.jp/en/.
About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The companys pursuit of innovative solutions has produced an extensive list of patented products. Strecks core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit www.streck.com.